A

Business profile & competitive position

Agilent Technologies, Inc. operates as a Healthcare company in the Medical – Diagnostics & Research industry. Its business model centers on application-focused solutions for life sciences, diagnostics and applied markets, including analytical instruments, software, services and consumables that span the entire laboratory workflow. Following a November 2024 reorganization, the company now reports through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Sales reach end customers primarily through a direct sales force, supplemented by distributors, resellers, manufacturers’ representatives and e-commerce channels.

The company’s margin and returns profile suggests it has carved out meaningful pricing power in specialized analytical and diagnostic workflows. Net margin stands at 19.6%, while return on equity is 20.8%. A net margin above most industrial-equipment peers, paired with an ROE near 21%, indicates that Agilent converts revenue into shareholder returns efficiently and is not simply competing on price. These figures are consistent with a business that derives recurring value from consumables, services and instrument-software ecosystems rather than purely transactional hardware sales.

Financial posture

Agilent currently carries a market capitalization of $43.3 billion and trades at a trailing P/E of 30.7. That multiple places the stock in premium territory relative to the broader Healthcare hardware and diagnostics complex, so the market is already pricing in durable growth and margin resilience. The valuation is partly supported by the 19.6% net margin and 20.8% ROE cited above, which both sit above what commodity capital-equipment businesses typically deliver.

The stock’s beta is 1.23, meaning it has historically exhibited about 23% more volatility than the overall market. That sensitivity can amplify moves around earnings or macro catalysts. At the latest snapshot, the stock price is $153.43, the RSI is 65.1 and the 50-day exponential moving average is $139.77. The stock is trading above that moving average and the RSI is approaching but has not crossed the 70 level often viewed as short-term overbought territory. Investors following Agilent should weigh the quality of the margin and return profile against the premium P/E and elevated relative volatility.

Strategic priorities & outlook

Agilent’s most recent SEC 10-K filing outlines a strategy built around segment realignment and technology expansion. The company reorganized into three reportable segments in November 2024 to support what it calls a market-focused, customer-centric strategy. The segments are Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets.

Management has identified four operational priorities:

• Expand the liquid chromatography application space through new columns, new services and ongoing instrument and software product enhancements.
• Continue improving the mass spectrometry portfolio, specifically targeting performance, sensitivity, precision, robustness, ease of use and onboard intelligence.
• Advance software and service solutions to help customers operate a digitally connected smart lab that leverages data analytics, artificial intelligence and robotics.
• Run the business on a shared global infrastructure of centralized order fulfillment, supply chain, finance, IT, legal, procurement, workplace and HR functions.

As of October 31, 2025, Agilent employed approximately 18,100 people worldwide, with 6,300 in Life Sciences and Diagnostics Markets, 7,400 in Agilent CrossLab and 2,500 in Applied Markets. Its primary R&D and manufacturing footprint extends across California, Colorado, Delaware, Massachusetts, Texas and Vermont in the U.S., plus Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom. That geographic spread gives Agilent both diversified production capacity and currency and trade-policy exposure.

Macro & geopolitical exposure

As a Healthcare/Medical – Diagnostics & Research company, Agilent is exposed to several macro and geopolitical factors that routinely move the sector. Regulatory risk is central: laboratory instruments, diagnostic assays and related software face oversight from the FDA and equivalent agencies abroad, so changes in approval timelines, quality standards or enforcement priorities can affect product launches and revenue recognition.

Trade policy matters because Agilent manufactures in and ships to multiple continents. Tariffs on instruments, components or consumables between the U.S., China and Europe can alter gross margins and demand patterns. Supply-chain resilience is another theme, especially for specialized detectors, columns and electronic subcomponents used in mass spectrometry and chromatography systems.

Currency risk is also relevant. With a global direct-sales footprint and manufacturing across more than 10 countries, a stronger U.S. dollar can compress reported revenue from international markets, while a weaker dollar can help it. Finally, end demand is partly tied to academic, government and biopharma research budgets, so shifts in public R&D funding and private biotech capital-raising cycles can influence instrument purchasing decisions.

Recent developments

The most recent news flow heading into the August 26, 2026 earnings report is dominated by institutional positioning and earnings preview articles. On August 23, 2026, defenseworld.net reported that EP Wealth Advisors LLC acquired 11,685 shares of Agilent Technologies. The day before, August 22, 2026, the same outlet noted that Allworth Financial LP established a new $2.71 million position in the stock. These filings show new institutional money moving into the name shortly before the quarterly update.

On August 21, 2026, Zacks published a piece exploring analyst estimates for Agilent’s Q3 earnings beyond just revenue and EPS, and 247wallst.com ran a headline flagging an upcoming catalyst on August 26 that investors should not ignore. The timing is notable because the next earnings report is scheduled for after the close on August 26, 2026, with a consensus EPS estimate of $1.49.

Earnings behavior & post-earnings drift

Agilent has delivered an earnings surprise in six of its last eight reported quarters, translating to a 75% beat rate over that period, with an average surprise of 2.5%. The average five-day price move following those eight reports has been 5.1% to the upside, classifying the post-earnings drift as “up.”

The most recent quarter, reported May 27, 2026, was the standout. Agilent earned $1.49 per share against an estimate of $1.41, a 5.7% beat. The stock jumped 16.87% the next trading day and continued to 18.61% over the following five days. The February 25, 2026 report was the only clear miss in the last four quarters: actual EPS was $1.36 versus the $1.37 estimate, a 0.7% shortfall, and the stock fell 3.01% the next day and 3.35% through the next five days.

The November 24, 2025 report was a marginal beat at $1.59 versus $1.58431 (0.4% surprise), yet the initial reaction was positive at 2.34% the next day before the five-day drift turned slightly negative at -3.12%. The August 27, 2025 quarter printed exactly in-line with estimates at $1.37, but the market responded with a 5.28% one-day gain and an 8.25% five-day advance. That pattern shows that headline beats and misses do not always drive the entire post-report move; guidance, margin commentary and order momentum can push the stock even when EPS matches expectations.

With the next report set for August 26, 2026 after the close and the market’s real expectation centered on EPS of $1.49, the earnings-history data suggests the stock has recently traded with sensitivity to both directional beats and the quality of forward commentary. The 5.1% average post-earnings drift and the 16.87% single-day move in May underline that earnings days for Agilent can carry meaningful price impact.

For a deeper dive into how buy-side and sell-side firms are interpreting Agilent’s premium valuation, upcoming earnings setup and sector positioning, explore the full institutional verdict on the ticker page.